Remimazolam Besylate Versus Dexmedetomidine As a Sedative in ICU Patients Undergoing Mechanical Ventilation: A Multicenter, Single-blinded, Randomized, Noninferiority Trial

右美托咪定 医学 镇静 麻醉 装载剂量 镇静剂 心动过缓 机械通风 咪唑安定 不利影响 重症监护室
作者
Wenfeng Cheng,Yinyin Chen,Faming He,Jingge Zhao,Zhengrong Mao,Bingyu Qin,Chunhua Hu,Shengnan Feng,Fan Zhang,Xin Dong,X Li,Baoquan Zhang,Ting Yue,Mian Zhang,Yibin Lu,Jian Chen,Xiaoye Jin,Yinjiang Chang,P L Chen,Lihui Wang
出处
期刊:Critical Care Medicine [Lippincott Williams & Wilkins]
卷期号:54 (3): 496-506
标识
DOI:10.1097/ccm.0000000000007011
摘要

OBJECTIVES: To evaluate whether remimazolam besylate could provide noninferior sedation to dexmedetomidine in patients under mechanical ventilation (MV) in the ICU. DESIGN: A multicenter, single-blind, randomized, noninferiority trial. SETTING: Fifteen ICUs across China between October 2021 and November 2023. PATIENTS: Adults under endotracheal intubation MV who were expected to require sedation for 8-48 hours. INTERVENTIONS: Three hundred fourteen patients were randomly assigned at a 1:1 ratio to the remimazolam besylate or dexmedetomidine group. Analgesia was provided via a continuous IV infusion of remifentanil at 1.2-9.0 µg/kg/hr. Remimazolam besylate or dexmedetomidine was administered IV at an initial loading dose of 0.1 mg/kg followed by a maintenance dose of 0.10-0.30 mg/kg/hr or at an initial loading dose of 0.20 µg/kg followed by a maintenance dose of 0.2-0.70 µg/kg/hr to achieve the targeted sedation range on the Richmond Agitation-Sedation Scale of -2 to +1. MEASUREMENTS AND MAIN RESULTS: Of the 314 patients enrolled, 299 completed the study. The sedation efficacy rates, as the primary endpoint, were 82.6% and 83.2% in remimazolam besylate and dexmedetomidine groups, respectively, in the per-protocol set (PPS), whereas the rate was 72.9% in both groups in the intention-to-treat (ITT) set. The noninferiority margin was set as 10%, and the lower limits of the two-sided 95% CI for the intergroup difference were -3.0% and -2.6% in the PPS and ITT sets, respectively. The dexmedetomidine group had a higher incidence of bradycardia than the remimazolam besylate group (4.7% vs. 0.7%; p = 0.029), whereas no intergroup differences were noted for the remaining secondary endpoints and adverse events. CONCLUSIONS: Remimazolam besylate could provide noninferior sedation as dexmedetomidine with a lower risk of bradycardia for 48 hours in mechanically ventilated patients in the ICU.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
蟹蟹里啦完成签到,获得积分10
刚刚
任性的皮卡丘完成签到,获得积分10
刚刚
liu完成签到,获得积分10
刚刚
医道无名完成签到 ,获得积分10
刚刚
失眠的霸完成签到,获得积分10
刚刚
啦啦完成签到,获得积分10
1秒前
syvshc的应助被CTx采纳,获得10
1秒前
KPL452B完成签到,获得积分10
1秒前
霸气的战斗机完成签到,获得积分10
1秒前
水滴完成签到,获得积分10
1秒前
柔弱的尔白完成签到,获得积分10
2秒前
舒适尔容完成签到,获得积分10
2秒前
张云完成签到 ,获得积分10
2秒前
张华完成签到,获得积分10
2秒前
科研通AI65的应助被sxguo采纳,获得10
2秒前
能干的cen完成签到,获得积分10
3秒前
4秒前
TING完成签到 ,获得积分10
4秒前
怡然念真发布了新的文献求助10
4秒前
逍遥小书生完成签到 ,获得积分10
4秒前
drughunter009发布了新的文献求助10
4秒前
关耳完成签到,获得积分20
4秒前
jinx完成签到,获得积分10
5秒前
DW的应助被YPHCC采纳,获得10
5秒前
Jayee完成签到,获得积分10
5秒前
5秒前
勤恳易真完成签到,获得积分10
5秒前
梵高晚风完成签到,获得积分10
6秒前
健壮豌豆完成签到,获得积分10
6秒前
zzf完成签到 ,获得积分10
6秒前
pikopiko完成签到,获得积分10
6秒前
安心欢愉完成签到,获得积分10
6秒前
LQQQ完成签到 ,获得积分10
7秒前
chengm123完成签到,获得积分10
7秒前
卡卡nlq发布了新的文献求助10
7秒前
7秒前
小苗儿完成签到,获得积分10
7秒前
yaya完成签到 ,获得积分10
7秒前
8秒前
李欣如完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180275
求助须知:如何正确求助?哪些是违规求助? 9570366
关于积分的说明 21810725
捐赠科研通 7776380
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479042